Patents by Inventor Rolf Peter Walker

Rolf Peter Walker has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Therapeutic agents
    Patent number: 8143263
    Abstract: A compound of Formula (I): is useful in the treatment or prevention of a disease or medical condition mediated through glucokinase (GLK or GK), leading to a decreased glucose threshold for insulin secretion.
    Type: Grant
    Filed: August 4, 2009
    Date of Patent: March 27, 2012
    Assignee: Astrazeneca AB
    Inventors: Stuart Norman Lile Bennett, Roger John Butlin, Leonie Campbell, Robert Darren Morse Davies, Graeme Richard Robb, Rolf Peter Walker, Michael James Waring, Helen Claire Pointon, Mikael Dan Brink, Jonas Rickard Fägerhag, Ulrik Jurva, Volker Schnecke, Anette Marie Svensson Henriksson, Christer Ralf Westerlund, Peter Gustaf Bonn
  • Therapeutic agents
    Patent number: 8071608
    Abstract: (2S)-2-[1-(2-Chloro-6-cyano-phenyl)pyrazolo[4,5-e]pyrimidin-4-yl]oxy-3-[(1R)-2-hydroxy-1-methyl-ethoxy]-N-(5-methylpyrazin-2-yl)propanamide or a pharmaceutically acceptable salt thereof is useful in the treatment or prevention of a disease or medical condition mediated through glucokinase (GLK or GK), leading to a decreased glucose threshold for insulin secretion.
    Type: Grant
    Filed: April 8, 2010
    Date of Patent: December 6, 2011
    Assignee: AstraZeneca AB
    Inventors: Stuart Norman Lile Bennett, Rolf Peter Walker, Michael James Waring
  • THERAPEUTIC AGENTS 927
    Publication number: 20100261733
    Abstract: (2S)-2-[1-(2-Chloro-6-cyano-phenyl)pyrazolo[4,5-e]pyrimidin-4-yl]oxy-3-[(1R)-2-hydroxy-1-methyl-ethoxy]-N-(5-methylpyrazin-2-yl)propanamide or a pharmaceutically acceptable salt thereof is useful in the treatment or prevention of a disease or medical condition mediated through glucokinase (GLK or GK), leading to a decreased glucose threshold for insulin secretion.
    Type: Application
    Filed: April 8, 2010
    Publication date: October 14, 2010
    Applicant: AstraZeneca AB
    Inventors: Stuart Norman Lile Bennett, Rolf Peter Walker, Michael James Waring
  • THERAPEUTIC AGENTS 414
    Publication number: 20100093757
    Abstract: A compound of Formula (I): is useful in the treatment or prevention of a disease or medical condition mediated through glucokinase (GLK or GK), leading to a decreased glucose threshold for insulin secretion.
    Type: Application
    Filed: August 4, 2009
    Publication date: April 15, 2010
    Applicant: AstraZeneca AB
    Inventors: Stuart Norman Lile BENNETT, Roger John Butlin, Leonie Campbell, Robert Darren Morse Davies, Graeme Richard Robb, Rolf Peter Walker, Michael James Waring, Helen Claire Pointon, Mikael Dan Brink, Jonas Rickard Fägerhag, Ulrik Jurva, Volker Schnecke, Anette Marie Svensson Henriksson, Christer Ralf Westerlund, Peter Gustaf Bonn